Skip to main content
  • linkedin
  • Newsroom
  • Career
  • Contact
Hit enter to search or ESC to close
Close Search
Aboleris PharmaAboleris PharmaAboleris Pharma
search
Menu
  • About us
  • Our Science
  • Patient’s Center
  • Investors
  • search
All Posts By

Laurel Wei

AbolerIS Pharma Announces First Patient Dosed in Part II of Phase 1 Study of ABO21009, a Novel Anti-CD45RC Antibody, for Rheumatoid Arthritis
News

AbolerIS Pharma Announces First Patient Dosed in Part II of Phase 1 Study of ABO21009, a Novel Anti-CD45RC Antibody, for Rheumatoid Arthritis

EULAR Congress 2025
Event

EULAR Congress 2025

AbolerIS Pharma Announces First Cohort Dosed in Phase 1 Study of ABO21009, a Novel Anti-CD45RC Antibody, for Rheumatoid Arthritis
News

AbolerIS Pharma Announces First Cohort Dosed in Phase 1 Study of ABO21009, a Novel Anti-CD45RC Antibody, for Rheumatoid Arthritis

AbolerIS Pharma Announces Formation of Scientific Advisory Board
News

AbolerIS Pharma Announces Formation of Scientific Advisory Board

ACR Convergence 2024
Event

ACR Convergence 2024

EULAR Congress 2024
Event

EULAR Congress 2024

AbolerIS is 4 years old!
News

AbolerIS is 4 years old!

Joint Belgian-Dutch Immunology Meeting 2023
Event

Joint Belgian-Dutch Immunology Meeting 2023

European Lifestars Awards
Event

European Lifestars Awards

BIO-EUROPE
Event

BIO-EUROPE

  • 1
  • 2
  • Next

© 2026 Aboleris Pharma. • Privacy • Cookie Policy • Terms and Conditions

Close Menu
  • About us
  • Our Science
  • Patient’s Center
  • Investors
  • Newsroom
  • Career
  • Contact
  • linkedin
Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}